fda warning bpc 157 peptide not approved for human use EVEXIAS Life Sciences filing lawsuit over peptides BPC-157 Legal Status: FDA Regulations

Allow vial to reach room temperature before preparation Draw 2ml bacteriostatic water using a sterile syringe Inject slowly down the inside wall of the vial Avoid foaming Gently swirl until fully dissolved Do not shake vigorously Label with the reconstitution date Refrigerate at 2C8C Protect from direct light exposure Protocol Overview Goal: Support Testicular Function, Fertility & Hormonal Balance Research Route: Subcutaneous Schedule: 3 Times Weekly Dose Range: 500 IU 2,000 IU Per Injection Reconstitution: 2ml BAC Water Final Concentration: 2,500 IU/ml Storage: Refrigerated After Reconstitution Reference Parameters (Standard-Dose protocol) For laboratory research only

For patients reading this: its understandable to be enticed by the promise of a quick fix for chronic pain or a faster injury recovery

2023 Apr 3

This triple mechanism distinguishes it from dual-agonist peptides like tirzepatide (GLP-1/GIP) and single-agonist compounds like semaglutide (GLP-1 only), making it the most broadly acting incretin-class compound currently under clinical investigation